DHAQ diacetate salt | 70711-41-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: DHAQ diacetate salt
• 英文别名: acetic acid;1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
• CAS: 70711-41-0
• 化学式: C24H32N4O8
• 分子量: 504.5
• InChiKey: MXBYMBHGTLEGPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.05
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  201
• 氢给体数：
  9
• 氢受体数：
  12

文献信息

• PURINONE DERIVATIVE
  申请人：Yamamoto Shingo

  公开号：US20130079327A1

  公开（公告）日：2013-03-28

  Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.

  由一般公式（I）表示的化合物（公式中的所有符号符合说明中的定义）是除了具有Btk选择性抑制活性外，还表现出优异的代谢稳定性，可以避免肝毒性或类似情况，从而可以为B细胞或肥大细胞参与的疾病提供安全的治疗药物。
• QUINOLINE DERIVATIVE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20160168121A1

  公开（公告）日：2016-06-16

  A compound represented by general formula (I) has a strong Axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for Axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.

  通式（I）所代表的化合物通过引入一种独特的双环结构，在其中饱和碳环与吡啶酮环融合，具有强烈的Axl抑制活性，并可作为Axl相关疾病的治疗剂，例如急性髓性白血病、黑色素瘤、乳腺癌、胰腺癌和胶质瘤、肾脏疾病、免疫系统疾病和循环系统疾病的治疗剂。
• Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2246048A1

  公开（公告）日：2010-11-03

  The present invention relates to pharmaceuticals and uses thereof directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.

  本发明涉及以 2,3-二甲氧基-5-甲基-6-（10-羟基癸基）-1,4-苯醌（艾地苯醌）为活性剂，用于治疗或预防原发性进行性多发性硬化症（PP-MS）的药物及其用途。
• BIOLOGICAL SELF-ASSEMBLED NANOCRYSTAL INJECTION HAVING LYMPHATIC TARGETING FUNCTION AND PREPARATION METHOD
  申请人：Shenzhen China Resources Jiuchuang Medical and Pharmaceutical Co., Ltd

  公开号：EP3643299A1

  公开（公告）日：2020-04-29

  A biological self-assembled nanocrystal injection having a lymphatic targeting function and an administration method for targeting a lymphatic system using the biological self-assembled nanocrystal injection. The injection comprises 0.05-5% of mitoxantrone and a salt thereof, 0.1-10% of an osmotic pressure regulator, 0.001-0.1% of a buffering agent, 0.01-0.1% of an antioxidant, 0.05-1% of an adsorbent, and 0-20% of a filler. The administration method is interstitial injection, and a lymph node will produce a blue color visible to the naked eye after passive targeting to the lymphatic system.

  一种具有淋巴靶向功能的生物自组装纳米晶体注射剂和一种使用生物自组装纳米晶体注射剂靶向淋巴系统的给药方法。该注射剂包括 0.05-5%的米托蒽醌及其盐、0.1-10%的渗透压调节剂、0.001-0.1%的缓冲剂、0.01-0.1%的抗氧化剂、0.05-1%的吸附剂和 0-20%的填充剂。给药方法是间隙注射，被动靶向淋巴系统后，淋巴结会产生肉眼可见的蓝色。
• HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY
  申请人：Shanghai Dude Medical Technology Co., Ltd

  公开号：EP3643716A1

  公开（公告）日：2020-04-29

  The present invention provides a class of novel compounds having Btk selective inhibitory activity, better metabolic stability and the like.

  本发明提供了一类具有 Btk 选择性抑制活性、更好的代谢稳定性等特点的新型化合物。